Shuiying Hu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7088378/publications.pdf

Version: 2024-02-01

77 papers	3,691 citations	117619 34 h-index	128286 60 g-index
78 all docs	78 docs citations	78 times ranked	4957 citing authors

#	Article	IF	Citations
1	Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer. Clinical Cancer Research, 2007, 13, 1161-1170.	7.0	362
2	Interaction of Imatinib with Human Organic Ion Carriers. Clinical Cancer Research, 2008, 14, 3141-3148.	7.0	207
3	Uncommon Mutation, but Common Amplifications, of thePIK3CAGene in Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4688-4693.	3.6	189
4	Suppression of BRAF/MEK/MAP Kinase Pathway Restores Expression of Iodide-Metabolizing Genes in Thyroid Cells Expressing the V600E BRAF Mutant. Clinical Cancer Research, 2007, 13, 1341-1349.	7.0	166
5	Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. International Journal of Cancer, 2006, 119, 2322-2329.	5.1	162
6	Crenolanib is active against models of drug-resistant FLT3-ITDâ˜positive acute myeloid leukemia. Blood, 2013, 122, 3607-3615.	1.4	159
7	Pharmacogenetic Pathway Analysis of Docetaxel Elimination. Clinical Pharmacology and Therapeutics, 2009, 85, 155-163.	4.7	148
8	Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters. Clinical Cancer Research, 2009, 15, 6062-6069.	7.0	146
9	Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide. Clinical Cancer Research, 2013, 19, 1458-1466.	7.0	128
10	High Prevalence and Possible de Novo Formation of BRAF Mutation in Metastasized Papillary Thyroid Cancer in Lymph Nodes. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5265-5269.	3.6	114
11	A phosphotyrosine switch regulates organic cation transporters. Nature Communications, 2016, 7, 10880.	12.8	100
12	Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy. Nature Communications, 2020, 11, 972.	12.8	86
13	Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5231-5236.	7.1	84
14	Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel. Clinical Cancer Research, 2012, 18, 4433-4440.	7.0	80
15	Conjunctive Therapy of Cisplatin With the OCT2 Inhibitor Cimetidine: Influence on Antitumor Efficacy and Systemic Clearance. Clinical Pharmacology and Therapeutics, 2013, 94, 585-592.	4.7	72
16	Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy. Clinical Cancer Research, 2019, 25, 6295-6301.	7.0	68
17	Phosphatidylinositol 3-Kinase/Akt Positively Regulates Fas (CD95)-Mediated Apoptosis in Epidermal Cl41 Cells. Journal of Immunology, 2006, 176, 6785-6793.	0.8	64
18	Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors. Clinical Cancer Research, 2013, 19, 236-246.	7.0	64

#	Article	IF	Citations
19	Detection of Serum Deoxyribonucleic Acid Methylation Markers: A Novel Diagnostic Tool for Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 98-104.	3.6	59
20	Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b. Cancer Research, 2015, 75, 2729-2736.	0.9	59
21	OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. Journal of Clinical Investigation, 2018, 128, 816-825.	8.2	57
22	Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide. Molecular Cancer Therapeutics, 2012, 11, 921-929.	4.1	54
23	Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1). Clinical Cancer Research, 2014, 20, 985-994.	7.0	54
24	Modulation of OATP1B-Type Transporter Function Alters Cellular Uptake and Disposition of Platinum Chemotherapeutics. Molecular Cancer Therapeutics, 2013, 12, 1537-1544.	4.1	51
25	Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia. Journal of the National Cancer Institute, 2011, 103, 893-905.	6.3	50
26	Influence of Drug Formulation on OATP1B-Mediated Transport of Paclitaxel. Cancer Research, 2014, 74, 3137-3145.	0.9	50
27	Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitroâ€“in vivo correlations. British Journal of Cancer, 2014, 110, 894-898.	6.4	47
28	Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. Journal of Clinical Investigation, 2020, 130, 4601-4606.	8.2	44
29	Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Molecular Cancer Therapeutics, 2008, 7, 1110-1120.	4.1	43
30	Silica-Induced Apoptosis in Alveolar Macrophages: Evidence of in Vivo Thiol Depletion and the Activation of Mitochondrial Pathway. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2006, 69, 1261-1284.	2.3	41
31	Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2016, 77, 1231-1243.	2.3	41
32	OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Research, 2017, 77, 2102-2111.	0.9	41
33	Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib. Clinical Cancer Research, 2013, 19, 4359-4370.	7.0	40
34	Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death. Cancer Research, 2016, 76, 117-126.	0.9	36
35	Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	33
36	Pharmacokinetic Considerations for New Targeted Therapies. Clinical Pharmacology and Therapeutics, 2009, 85, 208-211.	4.7	31

#	Article	IF	Citations
37	OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition. Clinical Pharmacology and Therapeutics, 2012, 92, 642-650.	4.7	28
38	Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clinical Pharmacology and Therapeutics, 2016, 99, 651-660.	4.7	27
39	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nature Communications, 2019, 10, 2189.	12.8	26
40	Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions. Drug Metabolism and Disposition, 2020, 48, 420-426.	3.3	26
41	Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. Cancers, 2021, 13, 766.	3.7	26
42	Regulation of Drug Transport Proteinsâ€"From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium. Clinical Pharmacology and Therapeutics, 2022, 112, 461-484.	4.7	26
43	Murine Pharmacokinetic Studies. Bio-protocol, 2018, 8, .	0.4	25
44	Regulation of OATP1B1 Function by Tyrosine Kinaseâ€"mediated Phosphorylation. Clinical Cancer Research, 2021, 27, 4301-4310.	7.0	24
45	Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy. Materials Science and Engineering C, 2019, 102, 113-123.	7.3	23
46	Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1. Clinical Pharmacology and Therapeutics, 2020, 107, 227-237.	4.7	23
47	Role for Drug Transporters in Chemotherapyâ€Induced Peripheral Neuropathy. Clinical and Translational Science, 2021, 14, 460-467.	3.1	20
48	Role of Mitochondria in Silica-Induced Apoptosis of Alveolar Macrophages: Inhibition of Apoptosis by Rhodamine 6g andN-acetyl-L-cysteine. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2007, 70, 1403-1415.	2.3	17
49	Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1090, 43-51.	2.3	16
50	DNA Methylationâ€Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. Clinical and Translational Science, 2021, 14, 137-142.	3.1	16
51	Role of SLC transporters in toxicity induced by anticancer drugs. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 493-506.	3.3	15
52	Drug transporters and anthracycline-induced cardiotoxicity. Pharmacogenomics, 2018, 19, 883-888.	1.3	14
53	Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation. Molecules, 2021, 26, 5500.	3.8	14
54	Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1. Frontiers in Pharmacology, 2021, 12, 644342.	3.5	12

#	Article	IF	Citations
55	Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice. Pharmacology Research and Perspectives, 2019, 7, e00534.	2.4	10
56	Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1168, 122591.	2.3	10
57	Contribution of membrane transporters to chemotherapyâ€induced cardiotoxicity. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 36-47.	2.5	10
58	Interaction Between Sex and Organic Anionâ€Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenibâ€Nâ€Oxide and Regorafenibâ€Glucuronide in Mice. Clinical and Translational Science, 2019, 12, 400-407.	3.1	9
59	In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors. Pharmaceutics, 2021, 13, 2004.	4.5	9
60	Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions. Reviews of Physiology, Biochemistry and Pharmacology, 2020, , 177-215.	1.6	6
61	Strategies to Reduce Solute Carrierâ€Mediated Toxicity. Clinical Pharmacology and Therapeutics, 2018, 104, 799-802.	4.7	5
62	Predicting Paclitaxel Disposition in Humans With Wholeâ€Body Physiologicallyâ€Based Pharmacokinetic Modeling. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 931-939.	2.5	5
63	Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake. Molecular Pharmacology, 2022, 101, 381-389.	2.3	4
64	Transporters and Toxicity: Insights From the International Transporter Consortium Workshop 4. Clinical Pharmacology and Therapeutics, 2022, 112, 527-539.	4.7	4
65	A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.. Journal of Clinical Oncology, 2020, 38, TPS12125-TPS12125.	1.6	3
66	Development and validation of a UPLC-MS/MS analytical method for dofetilide in mouse plasma and urine, and its application to pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2019, 172, 183-188.	2.8	2
67	Imaging-Based Characterization of a Slco2b1(-/-) Mouse Model Using [11C]Erlotinib and [99mTc]Mebrofenin as Probe Substrates. Pharmaceutics, 2021, 13, 918.	4.5	2
68	Genetic and Pharmacological Inhibition of OCT2 Protects Rats against Oxaliplatinâ€induced Peripheral Neuropathy. FASEB Journal, 2019, 33, 813.9.	0.5	1
69	A phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer.. Journal of Clinical Oncology, 2020, 38, TPS12128-TPS12128.	1.6	1
70	Targeting drug transporters to prevent chemotherapy-induced peripheral neuropathy. Molecular and Cellular Oncology, 2021, 8, 1838863.	0.7	1
71	Abstract 14035: Renal Tubular Secretion and Cardiac Distribution of Dofetilide is Dependent on MATE1 Function. Circulation, 2020, 142, .	1.6	1
72	Preclinical Evaluation of Sorafenib in Combination with Cytarabine and Clofarabine in Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 4202-4202.	1.4	0

#	Article	IF	Citations
73	TAK1 is a Regulator of Sorafenibâ€induced Keratinocyte Toxicity. FASEB Journal, 2013, 27, 657.1.	0.5	0
74	Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	0
75	Epigenetic Regulation of OCTN1â€mediated Cytarabine Transport in Acute Myeloid Leukemia. FASEB Journal, 2019, 33, 675.2.	0.5	0
76	Role of OATP2B1 in Drug Absorption and Drugâ€Drug Interactions. FASEB Journal, 2019, 33, 507.7.	0.5	0
77	Role of transporters and S100A8/A9 in paclitaxelâ€induced peripheral neuropathy. FASEB Journal, 2020, 34, 1-1.	0.5	0